Pharmacogenomics of platinum-based chemotherapy response in NSCLC: A genotyping study and a pooled analysis

Oncotarget

Volumn 7, Issue 34, 2016, Pages 55741-55756

  Chen, Juan ^a,b   Wang, Zhan ^a   Zou, Ting ^a   Cui, Jiajia ^a   Yin, Jiye ^a,b   Zheng, Wei ^a   Jiang, Wuzhong ^a   Zhou, Honghao ^a,b   Liu, Zhaoqian ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Hunan Province Cooperative Innovation Center for Molecular Targeted New Drug Study   (China)

Author keywords

Chemotherapy response; Meta analysis; NSCLC; Platinum; Polymorphism

Indexed keywords

GEMCITABINE; GENOMIC DNA; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; XRCC1 PROTEIN; DNA BINDING PROTEIN; DNA REPAIR PROTEIN XRCC1; PLATINUM; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 3; XRCC1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; DNA EXTRACTION; DRUG SENSITIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; AGED; DNA REPAIR; GENETICS; LUNG TUMOR; META ANALYSIS; MIDDLE AGED; PHARMACOGENETICS;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHARMACOGENETICS; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

EID: 84981233815     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9688     Document Type: Article

References (71)

1. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015; 65:5-29.
2. Lebwohl D and Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1998; 34:1522-1534.
3. Bunn PA, Jr. and Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clinical cancer research. 1998; 4:1087-1100.
4. Chen J, Yin JY, Li XP, Wang Y, Zheng Y, Qian CY, He H, Fang C, Wang Z, Zhang Y, Xiao L, Wang SY, Zhang W, Zhou HH and Liu ZQ. Association of Wnt-Inducible Signaling Pathway Protein 1 Genetic Polymorphisms With Lung Cancer Susceptibility and Platinum-Based Chemotherapy Response. Clinical lung cancer. 2015; 16:298-304 e291-292.
5. Li XP, Yin JY, Wang Y, He H, Li X, Gong WJ, Chen J, Qian CY, Zheng Y, Li F, Yin T, Gong ZC, Zhou BT, Zhang Y, Xiao L, Zhou HH, et al. The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35:8259-8265.
6. Wang Y, Yin JY, Li XP, Chen J, Qian CY, Zheng Y, Fu YL, Chen ZY, Zhou HH and Liu ZQ. The association of transporter genes polymorphisms and lung cancer chemotherapy response. PloS one. 2014; 9:e91967.
7. Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH and Schellens JH. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer. 2012; 118:2466-2475.
8. Zhang T, Sun J, Lv M, Zhang L, Wang X, Ren JC and Wang B. XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy. Asian Pacific journal of cancer prevention: APJCP. 2013; 14:701-705.
9. Feng J, Sun X, Sun N, Qin S, Li F, Cheng H, Chen B, Cao Y, Ma J, Cheng L, Lu Z, Ji J and Zhou Y. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta biochimica et biophysica Sinica. 2009; 41:429-435.
10. Chen S, Huo X, Lin Y, Ban H, Li W, Zhang B, Au WW and Xu X. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. International journal of hygiene and environmental health. 2010; 213:140-145.
11. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nunez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-smallcell lung cancer. Annals of oncology. 2004; 15:1194-1203.
12. Booton R, Ward T, Heighway J, Taylor P, Power F, Ashcroft L, Morris J and Thatcher N. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer. 2006; 106:2421-2427.
13. Pan JH, Han JX, Wu JM, Huang HN, Yu QZ and Sheng LJ. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxelcisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration; international review of thoracic diseases. 2009; 78:49-55.
14. Krawczyk P, Wojas-Krawczyk K, Mlak R, Kucharczyk T, Biernacka B and Milanowski J. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer-a pilot study. Folia histochemica et cytobiologica/Polish Academy of Sciences, Polish Histochemical and Cytochemical Society. 2012; 50:80-86.
15. Yan PW, Huang XE, Yan F, Xu L and Jiang Y. Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pacific journal of cancer prevention: APJCP. 2011; 12:2291-2294.
16. Wang J, Zhang Q, Zhang H, Wang Q, Yang X, Gu Y and Zhang S. [Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2010; 13:337-341.
17. Hong W, Wang K, Zhang YP, Kou JY, Hong D, Su D, Mao WM, Yu XM, Xie FJ and Wang XJ. Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabinebased chemotherapy for advanced non-small cell lung cancer in a Chinese Han population. Journal of Zhejiang University Science B. 2013; 14:207-215.
18. Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN and Yu QZ. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with nonsmall cell lung cancer. Respiration; international review of thoracic diseases. 2008; 75:380-385.
19. Huang SJ, Wang YF, Jin ZY, Sun JY and Guo ZL. Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35:4023-4029.
20. Zhao X, Zhang Z, Yuan Y and Yuan X. Polymorphisms in ERCC1 gene could predict clinical outcome of platinumbased chemotherapy for non-small cell lung cancer patients. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35:8335-8341.
21. Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J and Zhou Y. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. American journal of clinical oncology. 2010; 33:489-494.
22. Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM and Yu CJ. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. Journal of thoracic oncology. 2012; 7:973-981.
23. KimCurran V, Zhou C, Schmid-Bindert G, Shengxiang R, Zhou S, Zhang L and Zhang J. Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer. Advances in medical sciences. 2011; 56:30-38.
24. Hildebrandt MA, Gu J and Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert opinion on drug metabolism & toxicology. 2009; 5:745-755.
25. Cui Z, Yin Z, Li X, Wu W, Guan P and Zhou B. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis. BMC cancer. 2012; 12:71.
26. Wu J, Liu J, Zhou Y, Ying J, Zou H, Guo S, Wang L, Zhao N, Hu J, Lu D, Jin L, Li Q and Wang JC. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clinical cancer research. 2012; 18:3972-3981.
27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228-247.
28. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ and Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. American journal of human genetics. 2007; 81:559-575.
29. Bagos PG and Nikolopoulos GK. A method for metaanalysis of case-control genetic association studies using logistic regression. Statistical applications in genetics and molecular biology. 2007; 6:Article17.
30. DerSimonian R and Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemporary clinical trials. 2007; 28:105-114.
31. Mantel N and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute. 1959; 22:719-748.
32. Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557-560.
33. Begg CB and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50:1088-1101.
34. Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629-634.
35. Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Sun Y, Zhang XR, Xu BH and Lin DX. [XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2006; 28:196-199.
36. Jin ZY, Zhao XT, Zhang LN, Wang Y, Yue WT and Xu SF. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer. Genetics and molecular research: GMR. 2014; 13:7617-7625.
37. Zhang L, Ma W, Li Y, Wu J and Shi GY. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy. Genetics and molecular research: GMR. 2014; 13:228-236.
38. Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J and Yingfeng Z. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced nonsmall cell lung cancer patients. Lung Cancer. 2009; 65:230-236.
39. Xu C, Wang X, Zhang Y and Li L. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2011; 14:912-917.
40. Hong CY, Xu Q, Yue Z, Zhang Y and Yuan Y. [Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism]. Ai zheng = Aizheng = Chinese journal of cancer. 2009; 28:1291-1297.
41. Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, Chiari R, Garavaglia D, Tofanetti FR, Flacco A, Siggillino A, Baldelli E, Tonato M and Crino L. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. Journal of thoracic oncology. 2011; 6:2018-2026.
42. Chen X, Sun H, Ren S, Kim Curran V, Zhang L, Zhou S, Zhang J and Zhou C. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. Clinical & translational oncology. 2012; 14:207-213.
43. Li P, Wang YD, Cheng J, Chen JC and Ha MW. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015; 36:9465-9473.
44. Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC and Hwang TS. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer. 2004; 44:311-316.
45. Zhou M, Ding YJ, Feng Y, Zhang QR, Xiang Y and Wan HY. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine. Genetics and molecular research: GMR. 2014; 13:3310-3318.
46. Li D, Zhou Q, Liu Y, Yang Y and Li Q. DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Med Oncol. 2012; 29:1622-1628.
47. Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Sun Y, Xu BH and Lin DX. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer]. Zhonghua yi xue za zhi. 2005; 85:972-975.
48. Li XD, Han JC, Zhang YJ, Li HB and Wu XY. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs. Asian Pacific journal of cancer prevention: APJCP. 2013; 14:145-148.
49. Wu W, Li H, Wang H, Zhao X, Gao Z, Qiao R, Zhang W, Qian J, Wang J, Chen H, Wei Q, Han B and Lu D. Effect of polymorphisms in XPD on clinical outcomes of platinumbased chemotherapy for Chinese non-small cell lung cancer patients. PloS one. 2012; 7:e33200.
50. Peng Y, Li Z, Zhang S, Xiong Y, Cun Y, Qian C, Li M, Ren T, Xia L, Cheng Y and Wang D. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinumbased chemotherapy in advanced nonsmall-cell lung cancer patients. International journal of cancer Journal international du cancer. 2014; 135:2687-2696.
51. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V and Mavroudis D. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clinical lung cancer. 2009; 10:118-123.
52. Zhou F, Yu Z, Jiang T, Lv H, Yao R and Liang J. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Swiss medical weekly. 2011; 141:w13275.
53. Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacological research. 2016.
54. O'Grady S, Finn SP, Cuffe S, Richard DJ, O'Byrne KJ and Barr MP. The role of DNA repair pathways in cisplatin resistant lung cancer. Cancer treatment reviews. 2014; 40:1161-1170.
55. Gu AQ, Wang WM, Chen WY, Shi CL, Lu JH and Han JQ. XRCC1 genetic polymorphisms and sensitivity to platinumbased drugs in non-small cell lung cancer: an update metaanalysis based on 4708 subjects. International journal of clinical and experimental medicine. 2015; 8:145-154.
56. Sullivan I, Salazar J, Majem M, Pallares C, Del Rio E, Paez D, Baiget M and Barnadas A. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer letters. 2014; 353:160-166.
57. Lee SY, Kang HG, Yoo SS, Kang YR, Choi YY, Lee WK, Choi JE, Jeon HS, Shin KM, Oh IJ, Kim KS, Lee J, Cha SI, Kim CH, Kim YC and Park JY. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with firstline paclitaxel-cisplatin chemotherapy. Lung Cancer. 2013; 82:330-339.
58. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR and Wood AJ. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. The New England journal of medicine. 1989; 320:565-570.
59. Wood AJ and Zhou HH. Ethnic differences in drug disposition and responsiveness. Clinical pharmacokinetics. 1991; 20:350-373.
60. Mazerska Z, Mroz A, Pawlowska M and Augustin E. The role of glucuronidation in drug resistance. Pharmacology & therapeutics. 2016.
61. Kim HJ, Lee KY, Kim YW, Choi YJ, Lee JE, Choi CM, Baek IJ, Rho JK and Lee JC. P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement. BMC cancer. 2015; 15:553.
62. Huang YS, Xue Z and Zhang H. Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression. Med Oncol. 2015; 32:470.
63. Subhani S, Jayaraman A and Jamil K. Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2015; 71:37-45.
64. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Critical reviews in oncology/hematology. 2007; 63:12-31.
65. Booton R, Ward T, Heighway J, Ashcroft L, Morris J and Thatcher N. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and nonsmall cell lung cancer. Journal of thoracic oncology. 2006; 1:679-683.
66. Sun N, Sun X, Chen B, Cheng H, Feng J, Cheng L and Lu Z. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer chemotherapy and pharmacology. 2010; 65:437-446.
67. Lv H, Han T, Shi X, Yao Y, Qiu W, Yue L and Liang J. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer. Med Oncol. 2014; 31:86.
68. Danesi R, Altavilla G, Giovannetti E and Rosell R. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics. 2009; 10:69-80.
69. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, Del Tacca M, Peters GJ, Falcone A and Danesi R. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clinical cancer research. 2008; 14:1797-1803.
70. Krawczyk P, Kucharczyk T, Kowalski DM, Powrozek T, Ramlau R, Kalinka-Warzocha E, Winiarczyk K, Knetki-Wroblewska M, Wojas-Krawczyk K, Kalakucka K, Dyszkiewicz W, Krzakowski M and Milanowski J. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. Journal of cancer research and clinical oncology. 2014; 140:2047-2057.
71. Du Y, Su T, Zhao L, Tan X, Chang W, Zhang H and Cao G. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer. PloS one. 2014; 9:e99843.